Angiex Commences Phase I ADC Trial with Abzena's Clinical Materials

13 August 2024

Angiex’s AGX101 Phase I Clinical Trial Supported by Abzena’s Manufacturing Expertise

Angiex continues to make strides in cancer therapy development with its Phase I clinical trial for AGX101, a TM4SF1-targeted antibody-drug conjugate (ADC). This novel therapy aims to disrupt the blood vessels in tumors, addressing aggressive forms of cancer. The collaboration with Abzena, a leading contract development and manufacturing organization (CDMO), has been pivotal in providing the critical manufacturing capabilities needed to move this therapy into early clinical stages.

Manufacturing Chemist reported on this significant collaboration, recognizing Abzena’s role in advancing Angiex’s promising cancer therapy. As a specialized publication covering the latest in pharmaceutical manufacturing and development, Manufacturing Chemist is a key outlet for industry professionals. Their coverage underscores the importance of CDMOs in accelerating the production of innovative therapies like AGX101, contributing to the future of cancer treatment.


About Angiex

Angiex Inc. is a privately held biotech startup whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by a scientific team of leading experts in angiogenesis, vascular biology, and oncology. The company is developing a novel portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus or cytosol, where the site of payload action is located. This direct delivery holds the promise of enhancing the efficacy and therapeutic margin of conventional ADCs. The lead product, AGX101, has advanced through pre-clinical development and is about to begin Phase 1 clinical trials. To learn more about Angiex...